Focus: Vivex Biologics is a tissue-based biotechnology company headquartered in Atlanta, specializing in allograft and regenerative medicine solutions for neurological and musculoskeletal indications. The company operates at pre-commercial or early clinical stage with a focused pipeline of cell and tissue therapies.
Profile data last refreshed 14h ago · AI intelligence enriched 2w ago
Stable — net +1 jobs in 30d
7 added, 6 removed. Backfill posture.
Vivex presents a high-risk, high-upside opportunity for scientists committed to regenerative medicine who can tolerate early-stage uncertainty and limited near-term commercial visibility.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vivex Biologics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vivex Biologics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Vivex Biologics' VIA Disc® NP Meets Primary Endpoint in Pivotal, Sham-Controlled ASCEND Trial Published in Journal of Clinical Medicine - Orthopedics This Week
Vivex Biologics' VIA Disc® NP Meets Primary Endpoint in Pivotal, Sham-Controlled ASCEND Trial Published in Journal of Clinical Medicine Orthopedics This Week
Vivex Biologics Lobbying Profile, 2026 - OpenSecrets
Vivex Biologics Lobbying Profile, 2026 OpenSecrets
Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling - GlobeNewswire
Vivex Biologics Launches VIA Linx™, a Novel Self-Assembling GlobeNewswire
Vivex Biologics Publishes New Medicare Real-World Evidence - GlobeNewswire
Vivex Biologics Publishes New Medicare Real-World Evidence GlobeNewswire
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Hemp-Derived Extracellular Vesicles: A Novel Frontier in Nanomedicine and Therapeutics.
Nucleus Pulposus Allograft Supplementation in Patients with Lumbar Discogenic Pain: Initial 6-month Outcomes from a Prospective Clinical Pilot Study.
Showing 5 of 7 publications